Knowledge of MDMA effects and risks

The manuals converge on the need to recognise MDMA as a drug with both expected therapeutic effects and meaningful physiological risk. Across the extracts, MDMA is described as producing altered perception, changes in time perception, and common acute reactions such as anxiety, jaw clenching, thirst or dry mouth, nausea, dizziness, and difficulty concentrating. They also agree that facilitators need to distinguish these expected effects from toxicity or pathology, and to monitor for transient but potentially important changes in blood pressure, pulse, temperature, and mood. They also overlap strongly on safety awareness. All three sources highlight cardiovascular and serotonergic concerns, and two of them explicitly mention risks such as hyperthermia, hyponatremia, and the need to detect complications or escalate medically when needed. The IMAP manual places particular emphasis on medication reconciliation, washouts, and physician oversight, while the PTSD protocol frames risk knowledge through exclusion criteria covering cardiovascular, hepatic, neurologic, seizure, hyperthermia, hyponatremia, pregnancy, and substance use risk. The main differences are in emphasis and scope. The MP-12 extract gives the clearest list of subacute effects, including fatigue, low mood, weakness, and irritability, and notes mild anxiety or depressed mood in the days after dosing. The PTSD protocol is the most explicit about subjective therapeutic effects such as empathy, closeness, and well-being, and it uniquely mentions possible neurocognitive, hepatic, immune, and abuse-related risks.